SD-06 is primarily used in research settings as a selective inhibitor of soluble epoxide hydrolase (sEH), an enzyme involved in the metabolism of bioactive lipid mediators. By inhibiting sEH, SD-06 helps stabilize epoxyeicosatrienoic acids (EETs), which have anti-inflammatory, vasodilatory, and analgesic properties. This makes SD-06 a valuable tool in studying inflammatory diseases, neuropathic pain, and cardiovascular conditions. It has shown potential in preclinical models for reducing pain and inflammation without the side effects associated with traditional NSAIDs or opioids. Due to its ability to modulate endogenous pain and inflammation pathways, SD-06 is often used in pharmacological studies aiming to develop novel therapeutics for chronic pain and metabolic disorders.